CLINICAL INFORMATION PAM | impavido-us | https://static.wixstatic.com/media/a54292_3fac205a460d4c5d99ad47bd10eba953.jpghttps://static.wixstatic.com/media/a54292

top of page

Clinical Information - PAM

Primary Amebic Meningoencephalitis: What Have We Learned in the Last 5 Years?

Torn from the Headlines: Surviving the “Brain Eating Amoeba”

Primary Amoebic Meningoencephalitis: Neurochemotaxis and Neurotropic Preferences of Naegleria fowleri

Impavido® (miltefosine) is an FDA-approved treatment for cutaneous, mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO

bottom of page

IMPAVIDO

(miltefosine)

*U.S. residents only

®

Clinical Information - PAM